Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Université de Montréal

Status: Completed

Conditions: Primary Open Angle Glaucoma

Treatments: Drug: placebo; Drug: travoprost

Study type: Interventional

Funder types: Other

Identifiers

NCT01711177

OPM3117-Dubois/Pham

Details and patient eligibility

About

Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside.

The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal

Enrollment: 14 patients

Sex: All

Ages: 45 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• good systemic health
• irido-corneal angle open
• intraocular pressure more than 18 mmHg

Exclusion criteria

• having cardiovascular problem
• Hypertension or diabetes
• under systemic medication for high blood pressure
• had an ocular surgery in the past

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

14 participants in 3 patient groups

Normal control

Sham Comparator group

Description:

Normal patient placebo

Treatment:

Drug: placebo

Glaucoma suspect

Sham Comparator group

Description:

Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)

Treatment:

Drug: placebo

Newly diagnosed glaucoma

Experimental group

Description:

Treated with Travoprost (0.04%)

Treatment:

Drug: travoprost